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KEY MESSAGE
The development of gonadotrophins derived from menopausal urine (HMG) has undergone signiﬁcant im-
provement in permitting subcutaneous administration. The source of LH activity in HMGwas previously principally
of pituitary origin. In this paper, we report a randomized-controlled trial in which the HMG derives its LH ac-
tivity from placental HCG.
A B S T R A C T
In this prospective, controlled, randomized, multicentre, non-inferiority study, efﬁcacy and safety of two HMG preparations (Menopur®- Ferring and
Meriofert®- IBSA Institut Biochimique SA) for ovarian stimulation were compared (270 women undergoing IVF aged between 18 and 39 years; BMI
30 kg/m2 or less; less than three prior completed assisted reproduction technique cycles). A standard long down-regulation with gonadotrophin-
releasing hormone agonist protocol, with HCG triggering was used; primary end-point was total number of oocytes retrieved; attention was paid to
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1472-6483/© 2017 IBSA Institut Biochimique SA. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ovarian hyperstimulation syndrome (OHSS). No statistically signiﬁcant differences between the treatment groups were reported for most of the clini-
cally signiﬁcant end-points, including embryo quality, fertilization rate, implantation rate, ongoing pregnancy rate and live birth rate. Total number of
oocytes retrieved was higher in the new HMG group compared with the reference (11.6 ± 6.6 and 9.7 ± 5.9, respectively, with a 95% CI of the differ-
ence equal +0.43 to +3.43). Increased number of oocytes was obtained through a shorter stimulation, but HMG units per oocyte retrieved were equivalent.
The safety proﬁle of the products for frequency of ovarian hyperstimulation syndrome was the same. This study showed that the new HMG prepara-
tion is a viable alternative for conducting ovarian stimulation in IVF cycles.
© 2017 IBSA Institut Biochimique SA. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Induction of multifollicular growth in IVF treatment, or ovarian stimu-
lation, is essential for success, as IVF efﬁcacy correlates with the
number of fertilized oocytes obtained (Sunkara et al., 2011). Histori-
cally, IVF procedures have used protocols involving administration of
gonadotrophins to increase the number of oocytes available for fer-
tilization and eventual embryo transfer.
Original gonadotrophin preparations, available in pre-IVF times,
were deﬁned by their FSH and LH bioactivity, as they were licensed
before precise gonadotrophin assays existed (Lunenfeld, 1963;
Lunenfeld and Donini, 1966). This explains that the later prepara-
tions, i.e., highly puriﬁed HMG and FSH preparations, are by analogy
still deﬁned by FSH and LH bioactivity rather than content. For HMG
preparations, achieving equipotent LH bioactivity has progressively
become problematic because urines of ageing menopausal women
are markedly richer in FSH than LH. Hence, other sources of LH ac-
tivity became necessary. An existing highly puriﬁed HMG preparation,
Menopur® (Ferring Pharmaceuticals, St Prex Switzerland), uses HCG
of pituitary origin as source of LH bioactivity. Menopur serves as ref-
erence preparation in the present study. Conversely, a different new
HMG preparation, Meriofert®, studied here uses HCG extracted from
urine of pregnant patients as source of LH activity. One justiﬁcation
of the present study, therefore, is to compare HMG preparations having
different sources of HCG, from pituitary and trophoblastic origin, as
source of LH bioactivity.
Ovarian stimulation regimens for IVF generally achieve pituitary
desensitization (down-regulation) with a gonadotrophin-releasing
hormone (GnRH) analogue to prevent premature luteinization. Pitu-
itary downregulation with GnRH agonist is an effective way of recruiting
an adequate number of pre-ovulatory follicles for IVF (Hughes et al.,
1992).
Meriofert (IBSA Institut Biochimique SA) is a highly puriﬁed
menotrophin preparation containing 75 IU (or 150 IU) FSH and LH ac-
tivity per vial. Unlike other HMG preparations, which contain FSH and
LH/HCG from pituitary origin both extracted from urine of meno-
pausal women, Meriofert combines highly puriﬁed FSH extracted from
the urine of menopausal women and LH activity that is primarily pro-
vided by highly puriﬁed HCG of chorionic origin extracted from the
urine of pregnant women.
A previous study comparing Meriofert with Menopur in ovarian
stimulation for IVF (Alviggi et al., 2013), showed that Meriofert was
equivalent to Menopur in clinical efﬁcacy based on the total number
of oocytes retrieved (primary end-point). In that study, Meriofert was
more efﬁcient (fewer units of gonadotrophin for a same number of
oocytes and higher 17-beta oestradiol levels), compared with Menopur.
These results, however, raised concerns about the possibility of an
increased risk of ovarian hyperstimulation syndrome (OHSS) when
using Meriofert, thereby, justifying the new study reported here.
The aims of the present study were, therefore, to conﬁrm the non-
inferiority of Meriofert compared with Menopur with regard to clinical
outcome (the primary end point being the total number of oocytes re-
trieved); to compare the incidence of clinically signiﬁcant OHSS
according to Golan Criteria (Golan and Weissman, 2009) between pa-
tients treated with Meriofert or Menopur.
Materials and methods
Patients and study design
This prospective, investigator-blind, randomized, controlled, parallel-
group, multicentre, two-arm, non-inferiority study was conducted at
six fertility clinics in Denmark (two sites), France (one site), Hungary
(one site), Switzerland (one site) and UK (one site). The primary
outcome was deﬁned as the total number of oocytes retrieved. The
trial was assessor blinded, and all investigators, central assessors,
laboratory personnel and sponsor staff involved in analysing and in-
terpreting data were kept blinded to the treatment allocation
throughout the trial. Blinding was ensured by providing patients with
sealed and anonymous boxes with the study drug and avoiding any
contact between assessors and study drug. Drug dispensing and ac-
countability was carried out by dedicated personnel, such as appointed
pharmacists or study nurses.
Patients with infertility, planning to undergo IVF, with or without
intracytoplasmic sperm injection, who achieved successful down-
regulation (deﬁned as endometrial thickness <7 mm or serum
oestradiol level ≤50 pg/ml) with a standard GnRH-agonist long pro-
tocol regimen were selected for possible study inclusion between
March 2011 and April 2013. Pregnancy outcome data were collected
in the subsequent 9 months, whereas frozen embryo transfer data
were collected during the following 2 years.
The eligibility criteria were female age between 18 and 39 years,
body mass index (BMI) 30 kg/m2 or less, less than three prior com-
pleted ART cycles, baseline (day 2–3) FSH less than 10 IU/L and
oestradiol less than 80 pg/ml, and a normal uterine cavity as dem-
onstrated on recent hysteroscopy, sonohysterogram or
hysterosalpingogram.
Signiﬁcant exclusion criteria included primary ovarian failure or
poor responders (deﬁned as having fewer than three oocytes re-
trieved in a previous cycled or with a pre-ovulatory oestradiol serum
concentration of <500 pg/ml), polycystic ovarian syndrome, one or both
ovaries inaccessible for oocyte retrieval, ovarian cysts greater than
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10 mm, stage III or IV endometriosis, untreated hydrosalpinx, un-
treated thyroid disease, adrenal disease, severe impairment of renal
and or hepatic dysfunction and neoplasias. All patients who were
screened but excluded met one of these exclusion criteria.
The trial was carried out in accordance with the declaration of Hel-
sinki, the International Conference on Harmonization Guidelines for
Good Clinical Practice, and local regulatory requirements. The trial
protocol was approved by both the local regulatory authorities and
the independent ethics committees covering all participating centres
(Paris-France: Comité de protection des personnes CPP Ile de France
III, Ref. N. 2839, Approval date 26 October 2010; Budapest–Hungary:
Medical Research Council, Ethics Committee for Clinical Pharma-
cology, Ref. N. ETT ikt.sz.16750-0/2010-1017 EKL, approval date 22
September 2010; Aldridge, UK: National Research Ethics Service Ox-
fordshire REC B, Ref. N. 10/H0605/63, Approval date: 25 November
2010; Copenhagen and Odense, Denmark: The Biomedical Re-
search Ethics Commitees for the Capital Region, Ref. N. H-1-2010-
087, Approval date: 12 November 2010; Basel, Switzerland:
Ethikkommission beider Basel, Ref. N. EK: 237/10, Approval date 11
October 2010) . Written informed consent was obtained from each
patient before any trial-related examinations were initiated.
Before starting HMG administration (Meriofert, IBSA Institut
Biochimique SA or Menopur, Ferring Pharmaceuticals), patients un-
derwent standard down-regulation protocol to prevent endogenous
gonadotrophin production using a commercially available GnRH-
agonist (Suprefact®- Sanoﬁ Aventis, Buserelin, 0.2 mg/day or
Decapeptyl®-Ipsen, Triptorelin, 3.75 mg/day). Down-regulation was
started in the mid-luteal phase of the previous cycle, i.e., day 21 of
the cycle preceding the stimulation cycle. Concomitant treatment with
the oral contraceptive pill was allowed, but not mandatory.
Patients were evaluated using transvaginal ultrasound and oes-
tradiol measurements to determine down-regulation status. Patients
were considered to be down-regulated if the endometrial thickness
was les than 7 mm or serum oestradiol was 50 pg/ml or less
(185 pmol/l), and either no cysts were present on ultrasound or, if
present, were less than 10 mm diameter.
After conﬁrmation of down-regulation, patients were random-
ized to one of the two treatment groups, and were instructed on self-
administration and supplied with the assigned medication, with the
ﬁrst dose set at 150 IU for patients aged 35 years or less, or 225 IU
for patients aged greater than 35 years and commenced 0–3 days after
conﬁrmation of down-regulation. Administration of GnRH-agonist was
continued until HCG administration. Ovarian response to stimula-
tion was assessed by transvaginal ultrasound scans and oestradiol
serum measurements.
Tolerance to HMG preparations was evaluated by inspection of in-
jection sites and, in the case of pain, asking patients to assess post-
injection severity and duration.
Transvaginal ultrasound was carried out using a high-resolution
transvaginal probe. Measurements of all follicles 10 mm or wider in
diameter were made using two perpendicular diameters, including
the greatest diameter visualized. The mean of these two measure-
ments were recorded for each follicle and plotted on a folliculogram.
Oestradiol was measured with a commercially available immunoas-
say kit at each study site (Siemens Automatic Immunoassay System,
Paris, France; Beckman Coulter’s Access 2 Immunoassay System,
Aldridge, UK; Abbott Axsym System, Budapest, Hungary; AutoDelﬁa
Oestradiol assay, Odense, Denmark; Oestradiol II Cobas 6000, Co-
penhagen, Denmark; Elecsys Estradiol Roche Diagnostic, Basel,
Switzerland).
Daily gonadotrophin administration was continued until at least
two follicles had a mean diameter greater than 16 mm, serum oes-
tradiol levels greater than 400 pg/ml (or 1500 pmol/l), or both. Starting
on treatment day 5–7, the HMG dosage was adjusted according to
ovarian response, but coasting was not permitted.
Final luteinization and oocyte maturation were achieved through
injection of 10,000 IU of commercially available human derived HCG
(Gonasi-HP® IBSA Italia; Choriomon®, IBSA Institut Biochimique SA;
or Pregnyl®, MSD). A lower HCG dosage was allowed only in cases
with an increased risk of OHSS (peak oestradiol on the day of HCG
>3500 pg/ml).
Oocytes and partner/donor spermwere collected 34–36 h after HCG
administration. Oocytes were fertilized in vitro (IVF) with or without
intracytoplasmic sperm injection.
Progesterone administration began on the day of oocyte re-
trieval and continued as per centres’ normal IVF treatment standard
procedures (but not less than 14 days after embryo transfer). Three
centres administered vaginal capsules (Utrogestan®, Besins), 200 mg
three times/day, one centre used vaginal pessaries (Cyclogest®,
Aktavis), 200 mg twice a day and two centres used vaginal gel
(Crinone®, Merck Serono) 90 mg once a day.
All the cleaved embryos obtained were evaluated on culture day
2, irrespective of the planned transfer day. Evaluation consisted of
the assessment of blastomere number, degree of fragmentation (Grade
A: ≤ 10%; Grade B: > 10 to ≤25%; Grade C: > 25 to ≤50%; Grade D: >
50%) and cell division aspect (typical or non-typical). For statistical
analysis purposes, embryo scoring was categorized into four quality
classes: top-, good-, moderate- and poor-quality embryos.
Transfer of either cleavage stage embryos or blastocyst was per-
mitted. The number of embryos transferred was at the discretion of
the investigator in consultation with the patient and with reference
to national legislation. Supernumerary embryos were cryopreserved
by slow-freezing procedure in all centres but Basel where vitriﬁca-
tion of oocytes in the pronucleate stage was performed, according
to Swiss legislation. Two weeks after oocyte retrieval, serum HCG
levels were measured, even if bleeding had occurred.
In an attempt to obtain data that accurately reﬂect the actual in-
cidence and severity of OHSS in an IVF protocol, and to insure that
this information was captured at each centre under generally com-
parable conditions, OHSS was characterized for each patient at the
time of embryo transfer (early onset) and at the time of serum preg-
nancy test (late onset) using a standard OHSS evaluation form based
on updated Golan criteria (Golan and Weissman, 2009).
Ongoing pregnancy rate was deﬁned as a pregnancy showing ul-
trasound embryonic heart activity at 10–11 weeks after embryo
transfer. Pregnant patients were given a special form for collecting
information on pregnancy outcome and the newborn’ s health status
for completion by the patient’s gynaecologist or obstetrician. Through-
out the study, women recorded all adverse events and concomitant
medications in a diary.
As new guidelines on biological products require the analysis of
the immunogenic potential of therapeutic proteins, in two selected
centres (Basel and Budapest), serum samples for anti-FSH, anti-
HCG and anti-LH antibodies detection were collected. Patients who
did not get pregnant during the ﬁrst cycle of treatment in the main
protocol, and had no previous gonadotrophin exposure before en-
tering the study, were encouraged to undergo a second treatment
cycle, to be performed in the same clinic under the supervision of the
same investigator. For this second cycle, only Meriofert, and not
Menopur, was provided to these patients irrespective of which drug
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had been used for the ﬁrst cycle in order to preserve the blindness
of the index trial. Serum samples were drawn at baseline, i.e., before
starting any treatment, on the day of oocyte retrieval and on the day
of beta-HCG pregnancy test. Samples were stored at −20°C and
shipped to a centralized laboratory (Kymos Pharma Services SL, Bar-
celona). All serum samples were analysed by a speciﬁc and fully
validated electrochemiluminescence screening assays for the pres-
ence of anti-FSH, anti-HCG and anti-LH antibodies, following a multi-
tiered approach. Positive samples in the screening assay were analysed
by the corresponding conﬁrmatory assay. Positive samples on the con-
ﬁrmatory assay were titrated to determine the amount of antibodies
present in the sample.
Statistical analysis
The intention-to-treat population (ITT), i.e., all patients receiving at
least one dose of test product, was the primary population for the ef-
ﬁcacy analyses. Analyses were also carried out on the per protocol
population, i.e., all the patients who underwent oocyte retrieval, ex-
cluding major protocol deviators), as well as the population who
became pregnant.
The total number of oocytes retrieved 34–36 h after HCG admin-
istration, i.e., the primary end-point of the study, was used to test non-
inferiority of Meriofert versus Menopur. Least-squares means and
their associated SE were used to calculate the 95% conﬁdence in-
terval of the difference between the two groups. If the lower bound
of the 95% conﬁdence interval of the difference between means
(Meriofert minus comparator) was greater than −2.1, then Meriofert
was considered to be non-inferior to the comparator.
A multivariate analysis of variance was used to calculate the 95%
conﬁdence interval for the difference between treatment groups using
investigational centre, women’s age and bodymass index as covariates.
The primary efﬁcacy analysis, including the main effects (treatment
and investigational centre), was repeated with the addition of a treat-
ment group by centre interaction term.
For secondary continuous variables, statistical analyses were
carried out using analysis of variance (ANOVA) models with factor for
treatment group (Meriofert versus Menopur). For ordered categori-
cal variables, the effect of treatment group was analysed using the
Cochran–Mantel–Haenszel test, whereas, for non-ordered categori-
cal variables the Fisher’s exact test was used. P < 0.05 was considered
statistically signiﬁcant.
Incidence of adverse events was compared using Fisher’s exact
test for comparison of Meriofert versus Menopur. SAS software (SAS
Institute Inc., UK was used for all statistical calculations. The sample
size was calculated taking into account previous published papers of
studies conducted with the reference product (Platteau et al., 2008).
The sample size was calculated using the Schuirmann’s two one-
sided test, considering the total number of oocytes retrieved, according
to non-inferiority experimental design criteria and choosing a two-
sided alpha (0.05), a power of 80%, a clinically signiﬁcant difference
of 2.1 (20% of 10.5), a standard deviation of 5.9. According to this cal-
culation, a minimum of 250 patients were required to demonstrate
non-inferioritym, i.e., 125 patients per group. Taking into consider-
ation the randomization blocks and some possible drop outs, a total
of 270 patients were enrolled.
Eligible participants were randomized in blocks of four at each
site using a randomization list that was generated with Statistical
Analysis Software. Randomization numbers were assigned chrono-
logically. The investigators were asked to keep a record of the names
of the patients and their corresponding randomization numbers,
thereby allowing easy identiﬁcation of data in a patient’s ﬁle if re-
quired. The randomization code for each patient was provided to the
investigators in individual sealed envelopes for emergency use only,
i.e., in case of onset of a serious adverse event that required unblinding
of the treatment.
Results
Patients’ demographics
A total of 270 patients undergoing IVF were randomized to two groups:
Meriofert (n = 135) or Menopur (n = 135). The ITT population in-
cluded all the 270 patients, of whom 259 proceeded to oocyte retrieval
and 240 to embryo transfer (Figure 1). Ovarian stimulation was in-
terrupted for six patients in the Meriofert group (three owing to poor
response and three for risk of OHSS) and ﬁve patients in the Menopur
group (one for a protocol violation, one for poor ovarian response,
two for risk of OHSS and one for investigator decision). Embryo trans-
fer was not carried out for 10 patients randomized to Meriofert (seven
with failed fertilization, one for no progressing embryos and two for
risk of OHSS), and for nine patients randomized to Menopur (four for
failed fertilization, two for no progressing embryos, two for risk of
OHSS and one for poor embryo quality).
Among the participants who started an IVF cycle, i.e., ITT popu-
lation, 95.6% (n = 129/135) in the Meriofert group and 96.3% (n = 130/
135) in the Menopur group had oocyte retrieval after ovarian
stimulation. Three patients in the Meriofert group had only one ovary
accessible for oocyte retrieval. These patients were kept in the ITT
analysis, but they were excluded from the per protocol population
analysis. One patient in the Menopur group did not meet the exclu-
sion criterion ‘primary ovarian failure or women known as poor
responders’ and began the HMG treatment with a starting dose of
300 IU. She was included in the ITT analysis, but excluded from the
per protocol population analysis. As a result, the per protocol popu-
lation included 126 patients in the Meriofert group and 129 in the
Menopur group (Figure 1).
The two treatment groups were well matched in demography, base-
line characteristics, duration of infertility and infertility diagnosis
(Table 1). The mean age of patients was about 33 years in each treat-
ment group, and 93.3% (n = 126/135) of patients in each group were
white. The patients were generally healthy, with an average BMI of
about 24 kg/m2 in each treatment group. No signiﬁcant differences
were observed between the treatment groups for duration of infer-
tility, infertility diagnosis, basal FSH and oestradiol levels. Prior and
concomitant minor pathologies affected a wide range of body systems.
In each group, over 55% (n = 78/135 in the Meriofert group and n =
75/135 in the Menopur group) of patients reported at least one prior
or concomitant pathology, i.e., hyperprolactinaemia, hypothyroid-
ism, endometriosis, endometrial polyps, ovarian cysts, allergies to
antibiotics, metal or pollen. No notable differences in prior or con-
comitant medication use, i.e., anaestheics – the most frequently
reported concomitant medication, were reported between the two
treatment groups.
Primary end-point: total number of oocytes
In the ITT population, the mean (±SD) number of oocytes retrieved
was signiﬁcantly higher (P = 0.012) in women stimulated with Meriofert
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(11.6 ± 6.6) than in those stimulated with Menopur (9.7 ± 5.9) (Table 2).
The difference (Meriofert–Menopur) in mean number of oocytes re-
trieved was +1.9, with a 95% CI of the difference equal +0.43 to +3.43,
i.e., a 95% CI lower limit greater than the predeﬁned clinically sig-
niﬁcant difference of −2.1. These results were conﬁrmed in the per
protocol population patient analysis, for which the total number of
oocytes retrieved was 12.3 ± 6.2 in the Meriofert group and 10.1 ± 5.7
in the Menopur group (95% CI of the difference equal +0.68 to +3.61).
The HMG start dose, arbitrarily set according to age, was 150 IU/
day for women aged 35 years or younger and 225 IU or 150 IU,
depending on expected response, for women aged over 35 years
(Table 3). As seen, no difference was found in HMG start dose between
the two HMG preparation groups. For both HMG preparations, more
oocytes were retrieved in the younger age group receiving the lower
HMG dose. In each HMG dose group, more oocytes were retrieved
in women who received the HMG preparation, which obtained its LH
effects from HCG of chorionic origin.
Multiple regression analysis demonstrated that the clinic where
the treatment took place and BMI, but not patient age, were signiﬁ-
cantly correlated with the number of oocytes retrieved (P = 0.009 and
P = 0.025, for centre and BMI respectively).
Secondary end-points
No statistically signiﬁcant differences between Meriofert and Menopur
were seen for implantation rate (Table 4) and pregnancy outcome pa-
rameters, including positive serum pregnancy test rate, ongoing
pregnancy rate, delivery and live birth rate. Of the women who started
stimulation (ITT population), 33% (n = 45/135) in the Meriofert group
and 37% (n = 50/135) in the Menopur group achieved an ongoing
Figure 1 – Trial ﬂow chart and disposition of patients by trial visit.
aPoor ovarian response (n = 3); risk of ovarian hyperstimulation syndrome (OHSS) (n = 3).
bProtocol violation (n = 1); poor ovarian response (n = 1); OHSS risk (n = 2); continuation of the treatment not in the best interest of the
patient (n = 1).
cfailed fertilization (n = 7); risk of OHSS (n = 2); no progressing embryos (n = 1).
dfailed fertilization (n = 4); risk of OHSS (n = 2); no progressing embryos (n = 2); poor embryos quality (n = 1).
eOnly one ovary accessible for oocytes retrieval (n = 3).
fInappropriate enrolment (poor responder patient) (n = 1).
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Table 1 – Demographic characteristics of the intention-to-treat study population.
Demography Meriofert (n = 135) Menopur (n = 135)
Age (years)
Mean ± SD
33.3 ± 4.0 33.0 ± 4.2
Minimum–maximum, 21–39 21–39
Race, n (%)
White
126/135 (93.3) 126/135 (93.3)
Asian 8/135 (5.9) 6/135 (4.4)
Black 1/135 (0.7) 3/135 (2.2)
Body mass index (kg/m2)
Mean ±SD
23.7 ± 3.1 23.5 ± 3.2
Minimum–maximum 18.1–29.9 18.0–30.2
Basal FSH (IU/L), mean ± SD 6.7 ± 1.4 6.6 ± 1.6
Basal oestradiol (pg/ml), mean ± SD 47.0 ± 19.6 44.1 ± 18.7
Infertility duration (months), mean ± SD 49.7 ± 32.9 45.5 ± 33.1
Patients with previous fertility treatment Pregnancies, n (%) 14/135 (10.4) 10/135 (7.4)
Patients with previous spontaneous Pregnancies, n (%) 40/135 (29.6) 39/135 (28.9)
Infertility classiﬁcation, n (%)
Male factor 84/135 (62.2) 83/135 (61.5)
Tubal 40/135 (29.6) 33/135 (24.4)
Anovulatory 7/135 (5.2) 7/135 (5.2)
Endometriosis (stage I or II) 9/135 (6.7) 10/135 (7.4)
Unexplained 16/135 (11.9) 23/135 (17.0)
Othera 5/135 (3.7) 3/135 (2.2)
a Under the class ‘other’, were classiﬁed the single women (two in the Meriofert group and three in the Menopur group), one same sex couple (Meriofert
group) and two patients with luteal phase defect (both in the Meriofert group). P, not statistically signiﬁcant for any of the parameters (F-test [analysis of
variance] for continuous variables, Cochran–Mantel–Haenszel test with modiﬁed ridit scores for categorical variables).
Table 2 – Primary end-point, number of oocytes retrieved.
2 Meriofert Menopur 95% CI Predeﬁned Non-inferiority limit P-valuea
Total number of oocytes retrieved (ITT) 11.6 ± 6.6 9.7 ± 5.9 0.43; 3.43 −2.1 0.012
Total number of oocytes retrieved (PP) 12.3 ± 6.2 10.1 ± 5.7 0.68; 3.61 −2.1 0.004
Data are reported as (mean ± SD); intention-to-treat population: n = 135 in both the HMG-IBSA and in the Menopur group. Patient population: n = 126 in the
HMG-IBSA group; n = 129 in the Menopur group.
ITT, intentio-to-treat; PP, per protocol patient population.
a Fisher’s exact test for categorical variables.
Table 3 – Number of oocytes according to age and starting dose as covariate.
Treatment Age classes Starting HMG dose
150 IU (n = 190) 225 IU (n = 79) 300 IU (n = 1) Total (n = 270) P-value between treatments
adjusted for age classes
n Mean (SD) n Mean (SD) n Mean (SD) Mean (SD)
Meriofert
(n = 135)
≤35 years
(n = 84)
84 11.77 (6.76) 0 – 0 – 11.77 (6.76) 0.011
>35 years
(n = 51)
8 12.75 (6.30) 43 11.14 (6.43) 0 – 11.39 (6.37)
Menopur
(n = 135)
≤35 years
(n = 91)
91 10.10 (6.06) 0 – 0 – 10.10 (6.06)
>35 years
(n = 44)
7 8.86 (5.81) 36 9.00 (5.61) 1 5.00 (-) 8.89 (5.54)
P-value between treatments adjusted for
starting HMG dose
0.012
P-value between treatments adjusted for
age classes and for starting HMG dose
0.012
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pregnancy. The live birth rate with Meriofert versus Menopur was 33%
(n = 44/135) versus 36% (n = 49/135) (Figure 2A). The delivery and
the live birth rate were the same as all the patients gave birth to at
least one living baby. Similar results were reported for the per pro-
tocol population (Figure 2B). No differences were found in the
proportion of women having day 2–3 and 5–6 embryo transfers between
the two HMG preparation groups (Table 4).
Although no statistically signiﬁcant difference were found in the
total and mean daily units of HMG used (Table 4), the duration of the
stimulation was shorter in the Meriofert group. The increased number
of oocytes and mature (MII) oocytes retrieved in the Meriofert group
was also associated with an increased number of cleaved embryos
obtained (Table 4). Embryo quality was equivalent in the two treat-
ment groups (Table 5). It is of interest that, throughout the stimulation,
17-beta oestradiol levels were statistically higher in the Meriofert group
(Figure 3).
Patients who did not achieve a live birth from their fresh trans-
fer owing to failure of implantation or miscarriage and had
supernumerary embryos frozen, or who had all their embryos frozen
because of risk of OHSS, were able to undertake a frozen embryo
transfer. The statistically signiﬁcantly higher number of oocytes and
cleaved embryos obtained with Meriofert translated into a higher
number of cryopreserved embryos available for subsequent trans-
fer. A total of 39 patients in the Meriofert and 28 patients in the
Menopur group underwent frozen embryo transfer, resulting in 13
(33.3%) and 6 (21.4%) ongoing clinical pregnancies. The cumulative
pregnancy rate was 43% (n = 58/135) with Meriofert and 41.5% (n =
56/135) with Menopur for the ITT population (Figure 2A), and 46% (n
= 58/126) and 43% (n = 56/129), respectively, for the per protocol patient
population (Figure 2B). One patient had miscarried in the Meriofert
group, therefore the live birth rate per frozen transfer resulted to be
30.8% (n = 12/39) in the Meriofert group and 21.4% (n = 6/28) in the
Menopur group. No statistically signiﬁcant difference in the cumu-
lative live birth rate was present (Figure 2A and 2B).
Safety parameters
Adverse events were reported by 42.2% (n = 57/135) versus 43.7% (n
= 59/135) of the study patients, with a similar number of events re-
ported in each group (221 and 208 events in the Meriofert and Menopur
groups, respectively). No difference was reported in the frequency
of the adverse events with the exception of vascular disorders (hot
Table 4 – Clinical parameters.a
Variable Meriofert (n = 135) Menopur (n = 135) P-valuea
Total HMG units (IU) 2171.4 ± 980.0 2303.6 ± 906.4 NS
Daily HMG dose (IU) 209.5 ± 77.3 215.4 ± 69.7 NS
HMG Units per retrieved oocyte (IU) 320.1 ± 564.6 359.0 ± 379.6 NS
Ovarian stimulation duration (days) 10.2 ± 1.3 10.6 ± 1.5 0.02
Follicles >16 mm on the HCG day (n) 5.0 ± 3.8 4.5 ± 3.2 NS
Mature (grade III–metaphase II) oocytes (n) 10.3 ± 6.0 8.2 ± 5.0 0.002
Ratio MII/total oocytes retrieved (%) 1334/1570 (85.0) 1060/1310 (80.9) 0.004
Inseminated-injected oocytes, (IVF + ICSI) (n) 10.8 ± 5.9 8.4 ± 5.0 <0.001
Inseminated oocytes, IVF (n) 4.3 ± 6.5 2.7 ± 4.7 0.02
Injected oocytes, ICSI (n) 6.5 ± 6.8 5.7 ± 5.7 NS
Fertilization rate/inseminated oocyte (%) 66.0 ± 22.6 66.5 ± 21.9 NS
Fertilization rate/retrieved oocyte (%) 57.9 ± 22.0 56.4 ± 21.5 NS
Cleaved embryos on day 2 (n) 5.8 ± 3.8 4.8 ± 3.7 0.04
Cleavage rate/inseminated oocyte (%) 56.9 ± 26.5 58.2 ± 27.4 NS
Cleavage rate/retrieved oocyte (%) 49.6 ± 24.3 49.4 ± 25.7 NS
Transferred embryos (n) 1.8 ± 0.6 1.7 ± 0.6 NS
Day of transfer:
Day 2–3: Cleavage stage, n (%) 97/119 (81.5) 104/121 (86.0) NS
Day 5–6: Blastocyst stage, n (%) 22/119 (18.4) 17/121 (14.0)
Frozen embryos (n) 3.1 ± 3.4 2.4 ± 3.3 NS
Implantation rate (%) 29.1 ± 41.0 28.2 ± 36.9 NS
Data are reported as (mean ± SD) if not otherwise speciﬁed.
ICSI, intracytoplasmic sperm injection; NS, not statistically signiﬁcant.
a F-test (analysis of variance) for continuous variables, Fisher’s exact test for categorical variables.
Table 5 – Embryo quality.a
Variable Meriofert (n = 120) Menopur (n = 123)
Number of patients with at least one top-quality embryo, n (%) 76/120 (63.3) 85/123 (69.1)
Mean number of top quality embryos per patient, Mean ± SD 1.54 ± 1.7 1.56 ± 1.7
Top quality (/total number of scored embryos), n (%) 185/704 (26.3) 192/605 (31.7)
Good quality (/total number of scored embryos), n (%) 191/704 (27.1) 169/605 (27.9)
Moderate quality (/total number of scored embryos), n (%) 255/704 (36.2) 195/605 (32.2)
Poor quality (/total number of scored embryos°), n (%) 73/704 (10.4) 49/605 (8.1)
a P-values, calculated with F-test (ANOVA) for continuous variables and Fisher’s exact test for categorical variables, were not signiﬁcant for all the vari-
ables. Total number of scored embryos: n = 704 in the Meriofert group; n = 605 in the Menopur group.
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ﬂushes) that were reported more often in the Meriofert group. The
most frequently reported treatment-related adverse events were as-
sociated with gastrointestinal disorders (abdominal pain, abdominal
distension and nausea) experienced by 20.7% (n = 28/135) of the pa-
tients in both treatment groups. These symptoms were deemed to
be probably caused by ovarian enlargement and are frequently re-
ported in IVF stimulation regimens. The next most frequently reported
adverse events were related to neurological system disorders (pre-
dominantly headache and dizziness), which were equally reported in
both groups. Fatigue and malaise were also reported in both treat-
ment groups with the same frequency, whereas hot ﬂushes were
reported more frequently in the Meriofert group (8.2% versus 1.5%,
P = 0.02).
No statistically signiﬁcant difference in the proportion of pa-
tients experiencing Serious adverse events was reported between the
Meriofert and Menopur groups (5.9% in both treatment groups). Only
four events in three patients in the Meriofert group (lower abdomi-
nal pain, constipation, ovarian hyperstimulation and ovarian torsion)
were considered to be related to the study drug. In the Menopur group,
only one case of moderate OHSS was considered to be related to the
study drug.
Sympomsn of OHSS were routinely checked on the day of embryo
transfer and on the beta-HCG test day; the results are reported in
Table 6. No difference in the frequency and severity of OHSS was de-
tected between the two treatment groups.
Follow-up data showed no difference in term of frequency and type
of adverse event occurred during pregnancy between the two treat-
ments. Information was collected for 57 newborns (born to 44mothers)
in the Meriofert group and 60 newborns (born to 49 mothers) in the
Menopur group.
Abnormalities at birth were reported for two babies in the Meriofert
group (congenital hand malformation with syndactyly for one baby and
single umbilical artery for the other) and one in the Menopur group
(reporting patent ductus arteriosus, intraventricular haemorrhage neo-
natal and neonatal respiratory distress syndrome).
Tolerability at the injection site was found to be very good in both
treatment groups, with few patients reporting pain (14 patients in the
Meriofert group versus 18 in the Menopur group), redness (seven pa-
tients versus 14 patients), tenderness (three patients versus eight
patients) or itching (one patient versus two patients). In those cases
reporting pain, the intensity was mainly mild and limited to the time
of injection.
Newborn safety
According to the pregnancy outcome forms collected, 93 deliveries
took place: 44 in the Meriofert group and 49 in the Menopur group
following fresh embryo tranfer. One patient in each treatment group
miscarried after the ﬁrst trimester. In the Meriofert group, of the 44
deliveries reported, 56.8% (n = 25/44) were caesarean and 43.2% (n
= 19/44) vaginal; 18.2% (n = 8/44) were preterm, i.e., before the 37th
week of gestation. In the Menopur group, 59.2% (n = 29/49) of deliv-
eries were caesarean and 40.8% (n = 20/49) vaginal; preterm delivery
was reported in 18.4% (n = 9/49) patients. Gestational age at deliv-
ery was 38.3 ± 2.8 weeks and 38.4 ± 2.6 weeks in the Meriofert and
Menopur group, respectively.
Figure 2 – Pregnancy and live birth data for the fresh and
cumulative, i.e., fresh plus frozen, cycles per the intention-to-treat
population (A) and the per-protocol population (B). P, not
statistically signiﬁcant for any of the parameters (Fisher’s exact
test for categorical variables); intention to treat population: n =
135 in both the Meriofert and in the Menopur group; per protocol
patient population: n = 126 in the Meriofert group; n = 129 in the
Menopur group. PP, per protocol population; ITT,
intention-to-treat.
Figure 3 – 17-beta oestradiol levels. Daily serum concentrations
(mean ± SE) of oestradiol during the administration of Meriofert
and Menopur. t-test for treatment difference based on log-
transformed values.
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A total of 117 babies were born, 57 in the Meriofert group and 60
in the Menopur group (Table 7). A total of 31 (70.5%) and 38 (77.6%)
babies respectively were singletons, whereas 26 versus 22 babies were
twins. No triplets were reported. A total of 15 (26.3%) and 13 (21.7%)
prematurely born babies, i.e., delivery before the 37th gestational week,
were reported in the Meriofert and Menopur group, respectively.
Among patients with a twin gestation, seven (53.8%) and four (36.4%)
had a premature delivery in the Meriofert and Menopur group, re-
spectively. The mean new-born weight was 2.82 ± 0.72 kg and 2.88
± 0.58 kg in the Meriofert and Menopur group, respectively. Two babies
(3.5%) in the Meriofert group and one (1.7%) in the Menopur group
reported abnormalities at birth (Table 7).
No statistically signiﬁcant differences were detected in any of the
parameters assessed, including the number of abnormalities de-
tected, which was in line with the known frequency for babies born
to patients undergoing fertility treatments.
Immunogenicity
A total of 126 samples from 25 patients from the study were analysed
to detect antibodies against FSH, LH and HCG. None of the 25 pa-
tients analysed had any positive samples for the presence of binding
antibodies against FSH and against LH.
Three patients had at least one positive sample for the presence
of binding antibodies against HCG, which were considered not clini-
cally relevant as one patient already had a positive result at the
beginning of the study (basal) and the remaining two patients had posi-
tive results during the study with the last sample returning below the
Table 6 – Ovarian hyperstimulation syndrome frequency and characteristics.
Symptoms Embryo transfer day Beta-HCG test day
Meriofert (n = 125) Menopur (n = 128) Meriofert (n = 129) Menopur (n = 130)
OHSS Symptoms, n (%)
Abdominal distension 25 (20.0) 28 (21.9) 16 (12.4) 17 (13.1)
Abdominal discomfort 12 (9.6) 14 (10.9) 7 (5.4) 8 (6.2)
Nausea 3 (2.4) 3 (2.3) 5 (3.9) 5 (3.8)
Vomiting – 1 (0.8) – –
Diarrhoea – – – 2 (1.5)
Ovarian enlargement
(>5 cm)
19 (15.2) 21 (16.4) 11 (8.5) 14 (10.8)
Ultrasonographic ascites 6 (4.8) 5 (3.9) 3 (2.3) 8 (6.2)
Clinical evidence of ascites – – 1 (0.8) –
Difﬁculty in breathing – – 1 (0.8) –
Change in blood volume – – 1 (0.8) –
Medical intervention 1 (0.8) – 1 (0.8) –
Outcome : recovered 1 (0.8) – 1 (0.8) –
OHSS Classiﬁcation, n (%)
No OHSS 92 (73.6) 90 (70.3) 112 (86.8) 105 (80.8)
Mild, grade 1 12 (9.6) 15 (11.7) 4 (3.1) 8 (6.2)
Mild, grade 2 15 (12.0) 18 (14.1) 10 (7.8) 9 (6.9)
Moderate, grade 3 6 (4.8) 5 (3.9) 2 (1.6)a 8 (6.2)a
Severe, grade 4 – – 1 (0.8)a –
P-values, calculated with Fisher’s exact test, were not signiﬁcant for all the assessed parameters. Dashes mean “0”.
a Two patients in the Meriofert group (one severe and one moderate) and six in the Menopur group (all moderate), were pregnant. OHSS, ovarian hyper-
stimulation syndrome.
Table 7 – Neonatal abnormalities.
Meriofert
(n = 57)
Menopur
(n = 60)
P- valuec
Body system/preferred term Na Nb % Na Nb %
Abnormality (all) 3 2 3.5 3 1 1.7 0.61
Congenital, familial and genetic disorders (all) 3 2 3.5 1 1 1.7 0.61
Congenital hand malformation 1 1 1.8 0 0 0.0 0.49
Patent ductus arteriosus 0 0 0.0 1 1 1.7 1.00
Single umbilical artery 1 1 1.8 0 0 0.0 0.49
Syndactyly 1 1 1.8 0 0 0.0 0.49
Nervous system disorders (all) 0 0 0.0 1 1 1.7 1.00
Intraventricular haemorrhage neonatal 0 0 0.0 1 1 1.7 1.00
Respiratory, thoracic and mediastinal Disorders (all) 0 0 0.0 1 1 1.7 1.00
Neonatal respiratory distress syndrome 0 0 0.0 1 1 1.7 1.00
a Total number of reported abnormalities.
b Number of babies with a reported event (one baby could have more than one abnormality).
c Fisher’s exact test.
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limit, indicating that no patient seroconverted during the study, i.e.,
no patient was positive at the end of the study.
The two positive responses were actually borderline and, as dis-
cussed, not conﬁrmed in subsequent analyses in the same patients.
Because of the high sensitivity of the assay, those low positive results
represented false positive results and were not considered clini-
cally relevant.
Discussion
The use of a new HMG preparation containing highly puriﬁed FSH and
highly puriﬁed HCG of chorionic origin, led to retrieve more oocytes,
MII oocytes and cleaved embryos in IVF than an established HMG ref-
erence comparator. These data suggest that gonadotrophins of
different origin and prepared differently, notably, gaining LH bioac-
tivity from HCG of different origin, can lead to signiﬁcant differences
in ovarian response to ovarian stimulation used in IVF. Interest-
ingly, these differences are encountered despite similar values in the
reference bio-efﬁcacy testing.
The results of the present trial showed that the new HMG prepa-
ration gaining LH bioactivity from HCG of chorionic origin provided
more oocytes, whereas showing a trend for shorter ovarian stimu-
lation duration that required less drug. This, therefore, equates to a
higher ovarian yield achieved with the new HMG preparation com-
pared with the reference preparation. Paralleling the above ﬁndings,
17-beta oestradiol levels were higher throughout ovarian stimula-
tion in women receiving HMG containing HCG of chorionic origin. These
results are concordant and conﬁrm those of a prior study (Alviggi et al.,
2013). Interestingly, the HMG units required to retrieve one single
oocyte were not different in the two groups, and the higher 17-beta
oestradiol levels did not increase the OHSS incidence. These, in some
way, contradictory results should increase awareness about the value
of purely statistical results, which should be treated with caution and
a more clinically sound approach, especially when secondary end-
points are concerned.
This Phase III trial is the ﬁrst multicentre, international, single blind,
controlled, randomized clinical trial comparing two highly puriﬁed HMG
preparations gaining their LH bio-activity from HCG of different origin.
Although the number of oocytes retrieved and the embryos ob-
tained was different, no statistically signiﬁcant differences were found
between the two treatment groups regarding fertilization and cleav-
age rates, quality of embryos obtained, implantation, ongoing and
cumulative pregnancy rates as well as delivery and live birth rates.
The strength of this study resides in the nature of its design – ran-
domized controlled trial – which anchors the validity of its conclusion:
more oocytes retrieved with the new HMG preparation. The fact that
this difference also translates into more mature oocytes and embryos
being obtained suggests that the new HMG preparation may also foster
higher cumulative IVF outcome.
The improved efﬁcacy of cryopreservation favours an increasing
preference for elective single embryo transfer to minimize multiple
pregnancy risks. This approach values the concept of ‘cumulative’ preg-
nancy rates achieved by each ovarian stimulation through both fresh
and frozen embryo transfers. In our study, the new HMG prepara-
tion and the reference product resulted in an equivalent ongoing and
cumulative pregnancy rates (33.3% versus 37.0% for ongoing and 43%
and 41.5% for cumulative, respectively). The weakness of the study,
however, is that it was not powered for comparing pregnancy rates
obtained with the two HMG preparations; therefore, additional studies
should be conducted to validate these ﬁndings.
Ideally, one would prefer that all in each ovarian stimulation
treatment groups received one common and identical HMG dose.
Such practice would, however, be ethically unacceptable, as possi-
bly unduly increasing OHSS risks. In our study, HMG start dose
was, therefore, set according to age: 150 IU/day in women 35 years
or younger, and 150–225 IU/day in women above that age for patient
safety reasons. The proportion of women receiving either the 150 IU/
day, or 225 IU/day dose between the two HMG groups was similar
(Table 3). Moreover, in all HMG start-dose groups, more oocytes
were retrieved in women receiving HMG gaining LH effects from
HCG of chorionic origin.
Our study accommodated the possibility that embryo transfer be
carried out on either day 2–3, or day 5–6 to accommodate practices
that each group was more familiar with. As shown in Table 4, there
were, however, no differences in proportion of day 2–3 and 5–6 trans-
fers between the two HMG groups.
The aim of ovarian stimulation in IVF is to produce an optimum
number of mature oocytes and embryos available for transfer. The
choice between the several different formulations of gonadotrophin
is between HMG and FSH-only preparations. HMG produced from the
urine of menopausal women contains equal FSH and LH bio-activity.
This is achieved today by addition of HCG of either pituitary or, tro-
phoblastic origin. FSH-only preparations are composed of either
urinary gonadotropins (highly puriﬁed FSH) or recombinant FSH, both
of which contain no LH activity. More recently, a long acting FSH
(corifollitropin alpha) has been developed for which further re-
search is being undertaken for speciﬁc subgroups of patients (Pouwer
et al., 2012). The latest Cochrane review (Farquhar et al., 2013), states
that all available gonadotrophin formulations are equally effective and
safe for ovarian stimulation in assisted reproduction technique cycles.
The choice of product will depend upon the availability, clinician pref-
erence, the convenience of its use and the associated costs. The same
conclusion is also drawn in the latest National Instituute for Health
and Care Excellence guidelines in which cost-effectiveness is spe-
ciﬁcally mentioned (NICE, 2013). In conclusion, this study demonstrated
that the new HMG preparation gaining LH bioactivity from HCG of cho-
rionic origin is a viable alternative for conducting ovarian stimulation
in IVF cycles.
Acknowledgement
The authors want to thank Isabelle Streuli, Vanessa Gayet, and all
the other sub-investigators and study nurses for their active role in
treating patients and managing the study.
A R T I C L E I N F O
Article history:
Received 26 August 2016
Received in revised form 22 March 2017
Accepted 22 March 2017
Declaration: The study was funded by
Institut Biochimique SA (IBSA). Trial
registration number: NCT01312766
(Clinicaltrial.gov). B Cometti and S
Trevisan are employees of IBSA.
26 R E P R O D U C T I V E B I O M E D I C I N E O N L I N E 3 5 ( 2 0 1 7 ) 1 7 – 2 7
Keywords:
HMG
HCG
Assisted reproduction
Ovarian stimulation
IVF
R E F E R E N C E S
Alviggi, C., Cognigni, G.E., Morgante, G., Cometti, B., Ranieri, A., Strina,
I., Filicori, M., De Leo, V., De Placido, G., 2013. A prospective,
randomised, investigator-blind, controlled, clinical study on the
clinical efﬁcacy and tolerability of two highly puriﬁed hMG
preparations administered subcutaneously in women undergoing
IVF. Gynecol. Endocrinol. 29, 695–699. doi:10.3109/
09513590.2013.788641. [2013 May 2]. Epub.
Farquhar, C., Rishworth, J.R., Brown, J., Nelen, W.L., Marjoribanks, J.,
2013. Assisted reproductive technology: an overview of cochrane
reviews. Cochrane Database Syst. Rev. (8), CD010537. doi:10.1002/
14651858.CD010537.pub2.
Golan, A., Weissman, A., 2009. Symposium: update on prediction and
management of OHSS. A modern classiﬁcation of OHSS. Reprod.
Biomed. Online 19, 28–32.
Hughes, E.G., Fedorkow, D.M., Daya, S., Sagle, M.A., Van de Koppel, P.,
Collins, J.A., 1992. The routine use of gonadotropin-releasing
hormone agonists prior to in vitro fertilization and gamete
intrafallopian transfer: a meta-analysis of randomized controlled
trials. Fertil. Steril. 58, 888–896.
Lunenfeld, B., 1963. Treatment of anovulation by human gonadotropins.
Int. J. Obstet. Gynecol. 1531–1559.
Lunenfeld, B., Donini, P., 1966. Historic aspects of gonadotropins in
induction of ovulation. In: Greenblatt, R.B. (Ed.), Ovulation. JB
Lippincott, USA, pp. 105–117.
NICE. 2013. Fertility: assessment and treatment for people with
fertility problems. National Institute for Clinical Excellence
and National Collaborating Centre for Women’s and Children’s
Health.
Platteau, P., Nyboe Andersen, A., Loft, A., Smitz, J., Danglas, P.,
Devroey, P., 2008. Highly puriﬁed HMG versus recombinant FSH for
ovarian stimulation in IVF cycles. Reprod. Biomed. Online 17, 190–
198.
Pouwer, A.W., Farquhar, C., Kremer, J.A., 2012. Long-acting FSH versus
daily FSH for women undergoing assisted reproduction. Cochrane
Database Syst. Rev. (6), CD009577. doi:10.1002/
14651858.CD009577.pub2.
Sunkara, S.K., Rittenberg, V., Raine-Fenning, N., Bhattacharya, S.,
Zamora, J., Coomarasamy, A., 2011. Association between the
number of eggs and live birth in IVF treatment: an analysis
of 400 135 treatment cycles. Hum. Reprod. 26,
1768–1774.
27R E P R O D U C T I V E B I O M E D I C I N E O N L I N E 3 5 ( 2 0 1 7 ) 1 7 – 2 7
